ConductScience.org, home

Comparison · NCT03640949-deaths

Vasopressin and Methylprednisolone vs Placebo: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Vasopressin and Methylprednisolone vs Placebo: deaths from any cause. Trial comparisons, record NCT03640949-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03640949-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.9030.8590.934wilson
Risk in group 20.8830.8380.916wilson
Risk difference, group 1 minus group 20.0204-0.03520.0748newcombe hybrid score
Risk ratio, group 1 over group 21.020.9631.09log
Odds ratio, group 1 over group 21.240.72.19log
Number needed to harm, for one more death from any cause on Vasopressin and Methylprednisolone than on Placebo49.1from the risk difference intervalthe interval includes no difference

Groups2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Vasopressin and Methylprednisolone
The study drugs will consist of 40 mg methylprednisolone (Solu-medrol®, Pfizer) and 20 IU of vasopressin (Empressin®, Amomed Pharma GmbH) given as soon as possible after the first dose of adrenaline. Additional doses of vasopressin (20 IU) will be administered after each adrenaline dose for a maximum of four doses (80 IU).~Vasopressin, Arginine: 20 IE of vasopressin per dose for a maximum of four doses (80 IU)~Methylprednisolone: 40 mg methylprednisolone once
214237EG000
Group 2Placebo
The placebo for vasopressin will consist of 1 mL of 9 mg/mL NaCl (normal saline) from 2 mL ampules identical to the vasopressin ampules. The placebo for methylprednisolone will also consist of 1 mL of 9 mg/mL NaCl.~NaCl: Placebo
233264EG001

Harm

What it counts
Total, all-cause mortality
Time frame

Source ClinicalTrials.gov

Trial

Title
Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest
NCT number
NCT03640949
Phases
PHASE2, PHASE3
Conditions
Heart Arrest
Interventions
Vasopressin, Arginine, Methylprednisolone, NaCl
Lead sponsor
Lars Wiuff Andersen
Results first posted
2022-01-11

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT03640949-deaths